Biocon Ltd shares rose 1.22% to ₹401.90 on the National Stock Exchange on Thursday, July 9, 2026, following the publication of clinical data for its Yesafili biosimilar in peer-reviewed journals.
The publication serves as a significant milestone for the Indian biotechnology firm, reinforcing the scientific backing for its lead product.
Yesafili, a biosimilar to Amgen’s Enbrel, received FDA approval with an interchangeable designation for its vial format in May 2024.
The recent publication of clinical data in academic journals provides additional visibility and credibility for the product as Biocon continues to expand its footprint in the competitive US biosimilar market.
This step is crucial for driving physician adoption and securing formulary placements.
The positive development comes as Biocon seeks to leverage its pipeline of biosimilars to drive growth.